The DOI matches its Crossref record; 30 of the 31 references it cites were found in a registry or an index.
Left Atrial Appendage Closure With the Watchman Device in Patients With a Contraindication for Oral Anticoagulation
Open accessAbstract
Objectives The purpose of this study was to assess the safety and efficacy of left atrial appendage (LAA) closure in nonvalvular atrial fibrillation (AF) patients ineligible for warfarin therapy.Background The PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation) trial demonstrated that LAA closure with the Watchman device (Boston Scientific, Natick, Massachusetts) was noninferior to warfarin therapy. However, the PROTECT AF trial only included patients who were candidates for warfarin, and even patients randomly assigned to the LAA closure arm received concomitant warfarin for 6 weeks after Watchman implantation.Methods A multicenter, prospective, nonrandomized study was conducted of LAA closure with the Watchman device in 150 patients with nonvalvular AF and CHADS₂ (congestive heart failure, hypertension, age ≥75 years, diabetes mellitus, and prior stroke or transient ischemic attack) score ≥1, who were considered ineligible for warfarin. The primary efficacy endpoint was the combined events of ischemic stroke, hemorrhagic stroke, systemic embolism, and cardiovascular/unexplained death.Results The mean CHADS₂ score and CHA₂DS₂-VASc (CHADS₂ score plus 2 points for age ≥75 years and 1 point for vascular disease, age 65 to 74 years, or female sex) score were 2.8 ± 1.2 and 4.4 ± 1.7, respectively. History of hemorrhagic/bleeding tendencies (93%) was the most common reason for warfarin ineligibility. Mean duration of follow-up was 14.4 ± 8.6 months. Serious procedure- or device-related safety events occurred in 8.7% of patients (13 of 150 patients). All-cause stroke or systemic embolism occurred in 4 patients (2.3% per year): ischemic stroke in 3 patients (1.7% per year) and hemorrhagic stroke in 1 patient (0.6% per year). This ischemic stroke rate was less than that expected (7.3% per year) based on the CHADS₂ scores of the patient cohort.Conclusions LAA closure with the Watchman device can be safely performed without a warfarin transition, and is a reasonable alternative to consider for patients at high risk for stroke but with contraindications to systemic oral anticoagulation. (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology [ASAP]; NCT00851578).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“occlusion may also reduce stroke risk in patients with contraindications to OAC. 454,455”
From 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS (2016) · cites this paper as [454]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Atrial fibrillation as an independent risk factor for stroke: the Framingham study
Wolf, P. A., Abbott, R. D., & Kannel, W. B. (1991) · Stroke · doi:10.1161/01.str.22.8.983 · Cited by 7,388
Heart Disease and Stroke Statistics—2012 Update: A Report From the American Heart Association
Writing Group Members, Roger, V. L., Go, A. S., Lloyd-Jones, D. M., Benjamin, E. J., Berry, J. D., Borden, W. B., Bravata, D. M., Dai, S., Ford, E. S., et al. (2012) · Circulation · doi:10.1161/cir.0b013e31823ac046 · Cited by 7,333
Gage, B. F., Waterman, A. D., Shannon, W., Boechler, M., Rich, M. W., & Radford, M. J. (2001) · JAMA · doi:10.1001/jama.285.22.2864 · Cited by 4,832
2012 focused update of the ESC Guidelines for the management of atrial fibrillation
Authors Task Force Members, Camm, A. J., Lip, G. Y. H., Caterina, R. D., Savelieva, I., Atar, D., Hohnloser, S. H., Hindricks, G., Kirchhof, P. F., Bax, J. J., et al. (2012) · EP Europace · doi:10.1093/europace/eus305 · Cited by 3,823
2012 focused update of the ESC Guidelines for the management of atrial fibrillation
Authors Task Force Members, Camm, A. J., Lip, G. Y. H., Caterina, R. D., Savelieva, I., Atar, D., Hohnloser, S. H., Hindricks, G., Kirchhof, P. F., Bax, J. J., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs253 · Cited by 2,929
Apixaban in patients with atrial fibrillation
Connolly, S. J., Eikelboom, J., Joyner, C., Diener, H.-C., Hart, R., Golitsyn, S., Flaker, G., Avezum, A., Hohnloser, S. H., Diaz, R., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1007432 · Cited by 2,483 · cited 1×
“In the AVERROES (Apixaban Versus Acetylsalicylic Acid to Prevent Strokes in Atrial Fibrillation Patients Who Have Failed or Are Unsuitable for Vitamin K Antagonist Treatment) study, warfarin-ineligible patients were randomly allocated to either aspirin or the factor Xa inhibitor, apixaban (21).”
MethodHolmes, D. R., Reddy, V. Y., Turi, Z. G., Doshi, S. K., Sievert, H., Buchbinder, M., Mullin, C. M., & Sick, P. B. (2009) · The Lancet · doi:10.1016/s0140-6736(09)61343-x · Cited by 2,242
Effect of clopidogrel added to aspirin in patients with atrial fibrillation
The ACTIVE Investigators (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0901301 · Cited by 2,102 · cited 2×
“Clopidogrel has been reported to reduce ischemic stroke by 32% (13).”
BackgroundMethodMant, J., Hobbs, F. R., Fletcher, K., Roalfe, A., Fitzmaurice, D., Lip, G. Y., & Murray, E. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61233-1 · Cited by 1,556
Wann, L. S., Curtis, A. B., January, C. T., Ellenbogen, K. A., Lowe, J. E., Estes, N. A. M., Page, R. L., Ezekowitz, M. D., Slotwiner, D. J., Jackman, W. M., et al. (2010) · Circulation · doi:10.1161/cir.0b013e3181fa3cf4 · Cited by 1,338
Cited by
Sorted by citations
Items 701–726 of 726
Zeitani, J., Likaj, E., Nazzaro, M. S., Dibra, A., Sievert, K., & Sievert, H. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm15010284
Ryuzaki, S., & Kondo, Y. (2025) · Nihon Naika Gakkai Zasshi · doi:10.2169/naika.114.207
Left Atrial Appendage Closure: Techniques and Devices
Hornung, M., & Sievert, H. (2026) · Springer eBooks · doi:10.1007/978-3-032-04995-7_35
Ognerubov, D. V., BERSENEVA, E., Cheberda, A. E., Абдыбекович, Ж. Б., Валерьевич, Б. В., Merkulova, I. A., Вольфович, П. Д., Ognerubov, N. A., & Merkulov, E. V. (2025) · Complex Issues of Cardiovascular Diseases · doi:10.17802/2306-1278-2025-14-6-28-38
Omic approach to atrial fibrillation
Puertas, R. D. (2017) · theses.fr (ABES) · doi:10.70675/dd1855ebz1421z42e4zb00czd5476f4de207
Left atrial appendage closure devices: a contemporary review of techniques, tips and tricks
Namjouyan, K., Virk, H. U. H., Rizwan, A. M., Khawaja, M., Alam, M., Strauß, M., & Krittanawong, C. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1767568
Anti-Thrombotic Therapy Following Transcatheter Structural Heart Intervention
Tartaglia, F. C., Antonelli, G., Gabrielli, A., Gitto, M., Khokhar, A. A., Soriente, F., Leone, P. P., Regazzoli, D., Backer, O. D., Mangieri, A., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15083175
Ali, I., Nasir, S., Nawaz, B., Hassan, S. U., Khan, H. Y., & Ullah, U. (2026) · The Healer Journal of Physiotherapy and Rehabilitation Sciences · doi:10.55735/0z2zep06
Simultaneous Closure of Left Atrial Appendage and Mitral Paravalvular Leak
Kay, R. T., Dave, P., Moroni, A., Al‐Shaibi, A., Kim, K., Ruiz, M., Vira, T., Alnasser, S. M., & Fam, N. P. (2026) · JACC Case Reports · doi:10.1016/j.jaccas.2026.108020
Magnocavallo, M., Awada, A., Vagnarelli, G., Rossi, P., Giabbani, I., Vireca, E., Vetta, G., Almorad, A., Chiricolo, G., Sorgente, A., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15103687
Niu, X., 汤希志, Fang, X., Liu, X., Xiang, X., Gao, H., Chen, Y., Song, Z., & Li, H. (2026) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2026.06.031
Wong, S., Broyd, C., Hanley, C., Bagnall, T., Abouelasaad, M., Cockburn, J., McCready, J. W., Arunothayaraj, S., Gomes, A., Hill, A., et al. (2026) · Journal of Cardiovascular Electrophysiology · doi:10.1111/jce.70433
Li, Y., & Liu, Y. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1881673
Jurinjak, S. J., Lukšić, V. R., Kopjar, T., & Velagić, V. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15145587
Sandeep, B., Cheng, H., Liu, X., Huang, X., Yan, Y., Jiang, F., Xiong, D., Wu, Q., Gao, K., & Xiao, Z. (2026) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2026.103398
Matvienko, G., Rimkienė, M. A., Bajoras, V., Drąsutienė, A., Masiulienė, R., Gabartaitė, D., Šalaševičienė, M., Matačiūnas, M., Sudavičienė, D., Marinskis, G., et al. (2026) · Medicina · doi:10.3390/medicina62091644
Effect of Left Atrial Appendage Closure on Cardiac Function
Wang, Q., Li, X., Zou, Q., Yu, F., Hu, H., Zhang, X., & Wang, Y. (2026) · Journal of Cardiovascular Development and Disease · doi:10.3390/jcdd13090425
Watching ‘AF’ter the Heart: the WATCHMAN TM device for atrial fibrillation
Choubey, U., Banker, H., Perry, G., Schaefer-Hood, G., Aggarwal, K., Upadrasta, V. A., Garg, A., & Jain, R. (2026) · Future Cardiology · doi:10.1080/14796678.2026.2724777
Recent Trials of Left Atrial Appendage Closure versus Oral Anticoagulants: An Optimistic View
Camm, A. J. (2026) · Thrombosis and Haemostasis · doi:10.1055/a-2945-5484
Mazzapicchi, A., Gallo, F., Zanarelli, L., Filice, F., Trichilo, M., Ielasi, A., Tespili, M., Grassi, M., Semeraro, G. C., Luca, G. D., et al. (2026) · Journal of Clinical Medicine · doi:10.3390/jcm15187181
Left Atrial Appendage Occlusion vs Direct Oral Anticoagulants for Atrial Fibrillation
Hiruma, Y., Aikawa, T., Kawamura, I., Iwagami, M., Kampaktsis, P., Briasoulis, Α., Hassanabad, A. F., Hosseini, K., Leone, P. P., Slipczuk, L. N., et al. (2026) · JACC Advances · doi:10.1016/j.jacadv.2026.103269
Left atrial appendage occlusion: an alternative to anticoagulation in atrial fibrillation
Messaoudi, Y., Roux, O., Monney, P. A., Müller, O., & Nietlispach, F. (2026) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2026.1889918
Chao, T., Lip, G. Y. H., Chan, Y., Lee, S., Li, M., Kim, D., Kuo, L., Okumura, K., Tse, H., Choi, E., et al. (2026) · Journal of Arrhythmia · doi:10.1002/joa3.70491
Interventioneller Vorhofohrverschluss zur Schlaganfallprophylaxe bei Vorhofflimmern
Meincke, F., Kreidel, F., Kück, K., & Bergmann, M. (2014) · Der Kardiologe · doi:10.1007/s12181-014-0563-2
Khamis, H., Ramzy, A., Elmelegy, N. A., El-Rabbat, K., & Masoud, A. (2015) · The Egyptian Heart Journal · doi:10.1016/j.ehj.2015.07.002
Metadata
- Authors
- Reddy, V. Y., Möbius-Winkler, S., Miller, M. A., Neuzil, P., Schuler, G., Wiebe, J., Sick, P., & Sievert, H.
- Affiliations
- Icahn School of Medicine at Mount Sinai (US)
- Leipzig Heart Institute (DE)
- Cardiovascular Center Frankfurt (DE)
- Krankenhaus Barmherzige Brüder (DE)
- Corresponding author
- Reddy, Vivek Y.
- Venue
- Journal of the American College of Cardiology
- Publisher
- Elsevier BV
- Published
- 2013-06
- Volume
- 61
- Issue
- 25
- Pages
- 2551-2556
- ISSN
- 0735-1097 (ISSN-L)
- OpenAlex
- W2115996784
- Cited by
- 727
- References
- 31
- Citations by year
- 2026: 25 · 2025: 28 · 2024: 46 · 2023: 51 · 2022: 43 · 2021: 57 · 2020: 48 · 2019: 59 · 2018: 61 · 2017: 72 · 2016: 83 · 2015: 75 · 2014: 59 · 2013: 17
- FWCI
- 52.98
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Journal of the American College of Cardiology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Boston Scientific
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cardiovascular and Diving-Related Complications
- Health Sciences › Medicine › Clinical Neurology › Acute Ischemic Stroke Management
- Keywords
- left atrial appendage closure, Watchman device, non-valvular atrial fibrillation, stroke prevention, systemic embolism, CHADS2 score, CHA2DS2-VASc score, bleeding risk, procedural safety, ischemic stroke, hemorrhagic stroke, anticoagulation alternatives
- MeSH terms
- Contraindications, Clopidogrel, Administration, Oral, Aged, Aged, 80 and over, Anticoagulants, Feasibility Studies, Female, Follow-Up Studies, Humans, Male, Platelet Aggregation Inhibitors, Prospective Studies, Ticlopidine, Treatment Outcome, Atrial Appendage
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
